Society Researchers Push Technology Barriers to ID Novel Treatment Strategy - Drug Discovery and Dev - National Multiple Sclerosis Society

Skip to navigation Skip to content

News

Share

Society Researchers Push Technology Barriers to ID Novel Treatment Strategy - Drug Discovery and Development

May 8, 2014

Researchers from Harvard and University of California at San Francisco funded by the National MS Society, among others, report that they have identified three small molecules that can stop immune cells called Th17 cells, which play a role in the immune attacks against the brain and spinal cord in MS. Collaborators identified these molecules by looking at “transcription factors” that instruct the activity of genes. The team used genome-wide screening techniques to find transcription factors that activate Th17 cells, and then looked for ways to inhibit these factors. Read more at Drug Discovery and Development magazine. 

About Multiple Sclerosis

Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.

Share